Abstract
This article discusses the properties of disorders of carbohydrate metabolism in elderly patients with gout. The results of examination of 60 patients who were divided by the HOMA index into two groups are presented. The significant disorders of carbohydrate metabolism during gout that are risk factors for the development of cardiovascular diseases are revealed.
Similar content being viewed by others
References
Alderman, M.N., Podagra, Uric Acid, and Cardiovascular Disease, Circulation, 2007, vol. 116, pp. 880–883.
Ansell, B.J., The Metabolic Syndrome: An Interplay of Multiple Subtle Cardiovascular Risk Factors, J. Clin. Outcomes Manage, 2002, vol. 9, no. 1, pp. 41–50.
Chen, S.Y., Chen, C.L., and Shen, M.L., Manifestations of Metabolic Syndrome Associated with Male Gout in Different Age Strata, Clin. Rheumatol., 2007, vol. 26, no. 9, pp. 453–457.
Choi, H.K., Ford, E.S., Li, C., and Curhan, G., Prevalence of the Metabolic Syndrome in Patients with Gout: The Third National Health and Nutrition Examination Survey, Arthr. Rheum., 2007, vol. 57.
De Fronzo, R.A. and Ferranninni, E., Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular Disease, Diabetes Care, 1991, vol. 14, pp. 173–194.
Dessein, P.H., Stanwix, A.E., Shipton, E.A., et al., Dislipidemia and Insulin Resistance in Gout: Sufficiently Common to Be Considered in the Evaluation and Management of Every Patient. III, in Conference of African League Against Rheumatism (AFLAR), September 1999, Ukenza, 1999.
Emmerson, B., Hyperlipidemia in Hyperuricemia and Gout, Ann. Rheum. Dis., 1998, vol. 57, pp. 509–510.
Feig, D.I., Kang, D., and Johnson, R., Uric Acid and Cardiovascular Risk, N. Engl. J. Med., 2008, vol. 359, pp. 1811–1821.
Ferns, G.A.A., Lanhan, J., Dieppe, P., and Galston, D.A., DNA Polymorphism of an Apoprotein Gene Associates with the Hypertriglyceridemia of Primary Gout, Hum. Genet., 1998, vol. 78, pp. 55–59.
Gaffo, A.L., Edwards, N.L., and Saag, K.G., Gout. Hyperuricemia and Cardiovascular Disease: How Strong is the Evidence for a Causal Link?, Arthr. Res. Ther., 2009, vol. 11, no. 4, pp. 240–249.
Gertler, M.M., Garn, S.M., and Levine, S.A., Serum Uric Acid in Relation to Age and Physique in Health and in Coronary Artery Disease, Ann. Intern. Med., 1951, vol. 34, pp. 1421–1431.
Grundy, S.M., Cleeman, J.L., and Daniels, S.R., Diagnosis and Management of the Metabolic Syndrome: An American Heart Association, Circulation, 2005, vol. 112, pp. 2735–2752.
Ioachimescu, A.G., Brennan, D.M., Hoar, B.M., et al., Serum Uric Acid Is an Independent Predictor of All-Cause Mortality in Patients at High Risk of Cardiovascular Disease, Arthr. Rheum., 2008, vol. 58, pp. 623–630.
Isomaa, B., Almgren, P., Tuomi, T., et al., Cardiovascular Morbidity and Mortality Associated with the Metabolic Syndrome, Diabetes Care, 2001, vol. 24, pp. 683–689.
Julius, S., Gudbrandsson, T., Jamerson, K., et al., The Hemodynamic Link between Insulin Resistance and Hypertension, J. Hypertens., 1991, vol. 9, pp. 983–986.
Khaodhiar, L., McCowen, K.C., and Blackburn, G.L., Obesity and Comorbid Conditions, Clin. Cornerstone, 1999, vol. 2, no. 3, pp. 17–31.
Koenig, W., Sund, M., Frohlich, M., et al., C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men: Results from the MONICA Augsburg Cohort Study, 1984 to 1992, Circulation, 1999, vol. 99, pp. 237–242.
Kuo, C.F., See, L.C., Luo, S.F., et al., Gout: An Independent Risk Factor for All-Cause and Cardiovascular Mortality, Rheumatology (Oxford), 2010, vol. 49, no. 1, pp. 141–146.
Liuzzo, G., Biasucci, L.M., and Gallimore, J.R., The Prognostic Value of C-Protein and Serum Amyloid in Severe Unstable Angina, N. Engl. J. Med., 1994, vol. 331, pp. 417–424.
Moriwalki, Y., Yamamoto, T., Takahashi, S., et al., Apolipoprotein E Phenotypes in Patients with Gout: Relation with Hypertriglyceridemia, Ann. Rheum. Dis., 1995, vol. 54, pp. 351–354.
Nesto, R., C-Reactive Protein, Its Role in Inflammation, Type 2 Diabetes and Cardiovascular Disease, and Effects of Insulin-Sensitizing Treatment with Thiazolidinediones, Diabet Med., 2004, vol. 21, pp. 810–817.
Puig, J.G. and Martinez, M.A., Hyperurecemia, Gout and the Metabolic Syndrome, Curr. Opin. Rheumatol., 2008, vol. 2, no. 2, pp. 187–191.
Rho, Y.H., Choi, S.J., Lee, Y.H., et al., The Prevalence of Metabolic Syndrome in Patients with Gout: A Multicenter Study, J. Korean Med. Sci., 2005, vol. 20, no. 6, pp. 1029–1033.
Takahashi, S., Moriwaki, Y., Tsutsumi, Z., et al., Increased Visceral Fat Accumulation Further Aggravates the Risk of Insulin Resistance in Gout, Metabolism, 2001, vol. 50, no. 4, pp. 393–398.
Wallace, S.L., Robinson, H., Masi, A.E., et al., Preliminary Criteria for the Acute Arthritis of Gout, Arthr. Rheum., 1977, vol. 20, pp. 895–900.
Yu, T.F. and Berger, L., Impaired Renal Function in Gout, Am. J. Med., 1982, vol. 72, pp. 95–100.
Author information
Authors and Affiliations
Corresponding author
Additional information
Original Russian Text © N.A. Kunitskaya, A.L. Ariev, 2012, published in Uspekhi Gerontologii, 2012, Vol. 25, No. 1, pp. 90–94.
Rights and permissions
About this article
Cite this article
Kunitskaya, N.A., Ariev, A.L. The properties of disorders of carbohydrate metabolism in elderly patients with gout and metabolic syndrome. Adv Gerontol 2, 336–339 (2012). https://doi.org/10.1134/S2079057012040108
Published:
Issue Date:
DOI: https://doi.org/10.1134/S2079057012040108